Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-Fluorocholine PET/CT

Journal of Nuclear Medicine

Volumn 57, Issue , 2016, Pages 55S-60S

  Beheshti, Mohsen ^a   Rezaee, Alireza ^a   Geinitz, Hans ^a   Loidl, Wolfgang ^a   Pirich, Christian ^b   Langsteger, Werner ^a  

^a St Vincent's Hospital   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

18F choline PET CT; 18F NaF PET CT; Bone metastasis; Prostate cancer

Indexed keywords

CHOLINE DERIVATIVE; FLUOROCHOLINE F 18; SODIUM FLUORIDE F 18; TRACER; UNCLASSIFIED DRUG; CHOLINE; FLUOROCHOLINE; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE;

ARTICLE; BIOACCUMULATION; BONE DISEASE; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER CELL; CANCER HORMONE THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEGENERATIVE DISEASE; HUMAN; INTERMETHOD COMPARISON; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSCLEROSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TISSUE PERFUSION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BONE TUMOR; CANCER STAGING; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; IMAGE ENHANCEMENT; MALE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE TUMOR; SECONDARY;

BONE NEOPLASMS; CHOLINE; EVIDENCE-BASED MEDICINE; HUMANS; IMAGE ENHANCEMENT; MALE; NEOPLASM STAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SODIUM FLUORIDE;

EID: 84991388013     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.169730     Document Type: Article

References (49)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61: 1079-1092.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
3. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med. 2007; 167: 2497-2502.
4. Fowler JE, Sanders J, Bigler SA, et al. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. J Urol. 2000; 163: 1467-1470.
5. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31: 578-583.
6. Nørgaard M, Jensen AO, Jacobsen JB, et al. A population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184: 162-167.
7. Beheshti M, Langesteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastasis. Semin Nucl Med. 2009; 39: 396-407.
8. 18F-fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011; 38: 14-22.
9. 18F-choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-933.
10. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002; 296: 580-583.
11. 18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33: 1387-1398.
12. 18F-fluorocholine PET. J Nucl Med. 2006; 47: 262-269.
13. 11C-choline PET/CT. J Nucl Med. 2006; 47: 1249-1254.
14. 11C] choline. J Nucl Med. 1997; 38: 842-847.
15. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998; 39: 990-995.
16. 11C-choline PET. J Nucl Med. 2000; 41: 1507-1513.
17. 18F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86: 1638-1648.
18. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623-628.
19. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31: 312-316.
20. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013; 54: 833-840.
21. Langsteger W, Beheshti M, Loidl W, et al. Fluor Choline (FCH) PET-CT in preoperative staging of prostate cancer [abstract]. Eur J Nucl Med Mol Imaging 2006; 33(suppl 2): 207-208.
22. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009; 11: 446-454.
23. Shen G, Deng H, Hu S, et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43: 1503-1513.
24. Beauregard JM, Williams SG, Degrado TR, et al. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol. 2010; 54: 325-332.
25. 18F-fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34: 1316-1317.
26. 18F-fluorocholine. Am J Nucl Med Mol Imaging 2015; 5: 96-108.
27. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012; 15: 45-55.
28. 11C-choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nucl Med Commun. 2014; 35: 20-29.
29. 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol. 2013; 48: 256-262.
30. 18F-choline PET/MRI. PLoS One 2014; 9: e101571.
31. 18F choline PET/MRI: combined SUV and ADC analysis. Ann Nucl Med. 2014; 28: 405-410.
32. 18F-choline PET/CT. Eur J Nucl Med Mol Imaging 2014; 41: 79-88.
33. 18F-FDG-PET/CT. Nucl Med Commun. 2015; 36: 1165-1173.
34. 18F-FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. Eur Radiol. 2014; 24: 2023-2030.
35. 18F-fluoride PET/CT. J Nucl Med. 2006; 47: 287-297.
36. 18F-NaF PET/CT. BJU Int. 2014; 114: 818-823.
37. Fogelman I. Skeletal uptake of diphosphonate: a review. Eur J Nucl Med. 1980; 5: 473-476.
38. 18F in rabbit bone. Clin Phys Physiol Meas. 1986; 7: 333-343.
39. 18F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging 2015; 42: 1767-1777.
40. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008; 49: 68-78.
41. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am. 2007; 45: 669-676.
42. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006; 36: 73-92.
43. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med. 1999; 29: 69-79.
44. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007; 37: 462-469.
45. 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35: 1766-1774.
46. 223Ra-chloride (Alpharadin). EJNMMI Res. 2011; 1: 4-6.
47. Kairemo K, Joensuu T. Radium-223-dichloride in castration resistant metastatic prostate cancer: preliminary results of the response evaluation using F-18-fluoride PET/CT. Diagnostics (Basel). 2015; 5: 413-427.
48. 18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55: 448-457.
49. 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013; 34: 935-945.